These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Steed M; Vidaillac C; Rybak MJ Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449 [TBL] [Abstract][Full Text] [Related]
49. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. Burnett YJ; Echevarria K; Traugott KA Ann Pharmacother; 2016 Dec; 50(12):1051-1059. PubMed ID: 27520326 [TBL] [Abstract][Full Text] [Related]
50. Antimicrobial Resistance and Molecular Epidemiology of Staphylococcus aureus Causing Bloodstream Infections at Ruijin Hospital in Shanghai from 2013 to 2018. Gu F; He W; Xiao S; Wang S; Li X; Zeng Q; Ni Y; Han L Sci Rep; 2020 Apr; 10(1):6019. PubMed ID: 32265473 [TBL] [Abstract][Full Text] [Related]
51. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus. Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155 [TBL] [Abstract][Full Text] [Related]
54. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study. Hammond J; Benigno M; Bleibdrey N; Ansari W; Nguyen JL Drugs Real World Outcomes; 2024 Jun; 11(2):273-283. PubMed ID: 38564101 [TBL] [Abstract][Full Text] [Related]
55. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Saravolatz L; Pawlak J; Johnson L Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042 [TBL] [Abstract][Full Text] [Related]
57. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694 [TBL] [Abstract][Full Text] [Related]
58. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis. Li Z; Zhuang H; Wang G; Wang H; Dong Y BMC Infect Dis; 2021 Jan; 21(1):74. PubMed ID: 33446122 [TBL] [Abstract][Full Text] [Related]
59. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080 [TBL] [Abstract][Full Text] [Related]
60. Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia? Kaye KS; Patel T; Drusano G Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31640979 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]